Navigation Links
Senior Research Analyst Richard Evans Joins AVOS Life Sciences
Date:9/12/2007

MORRISVILLE, N.C., Sept. 12 /PRNewswire/ -- AVOS Life Sciences announced today that Richard Evans has joined AVOS as Vice President. His primary responsibility will be providing advisory services to companies in the prescription drug and biotech areas as well as selected investment assignments in capital markets. As an Institutional Investor (II) rated drug analyst, he will also have responsibility for AVOS' emerging portfolio of research products in the capital markets area.

"Richard brings us a senior level perspective on the drug industry," said Neil MacAllister, president of AVOS Life Sciences. "His background in capital markets complements our team and helps position AVOS as one of the strongest research and analysis firms in the pharmaceutical industry."

Mr. Evans has received several national awards from publications such as Bloomberg Markets magazine. He has been profiled in Barron's and Street.com. Richard has also provided financial commentary for The Wall Street Journal, The New York Times, CNBC, CNN, and NPR.

Mr. Evans earned a master's degree in Public and Private Management from Yale University. He is also a Doctor of Veterinary Medicine, having received his degree from North Carolina State University.

"One of AVOS' strengths," continued MacAllister, "is our first hand experience gained through extensive consulting engagements delivering strategic, operational and financial insight to healthcare and drug companies. Richard's expertise in analyzing financial market conditions will greatly add to AVOS' ability to deliver actionable recommendations to our clients by providing them with a full understanding of capital market reaction."

AVOS Life Sciences, LLC is a healthcare consulting and research firm located in Morrisville, North Carolina, and New York, New York. The company helps clients understand the rapidly evolving pharmaceutical, biotechnology, medical device and diagnostic market segments, thereby assisting with strategic business development and investment decisions. AVOS' analytical tools are structured to assist with real-time decision-making in a dynamic environment.

AVOS' proprietary approach includes knowledge obtained through coverage of leading industry events, access to internal and external healthcare databases and the analysis and perceptive commentary of a network of experts such as leading pharma executives, global regulatory specialists, manufacturing and reimbursement consultants, and a team of analytical scientists.

For more information on Richard Evans joining AVOS, please contact kgriffin@avoslifesciences.com

http://www.avoslifesciences.com


'/>"/>
SOURCE AVOS Life Sciences, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. SecurePipe appoints two senior execs
2. Third Wave announces two senior management appointments
3. Senior Wisconsin stem-cell researcher leaves for Connecticut
4. Sonic Foundry names new senior vice president
5. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
6. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
7. Control Your siRNA Research
8. Getting Started with MicroRNA Research
9. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
10. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
11. Research Organics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):